NRIX Live signals | Maximize Profits with Getagraph.com

BUY 157701 min ago

@ $9.02

Issued: 14 Feb 2024 @ 14:04

Return: 74.61%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 0.89 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Today's Volume	1.63M
Average Volume	1.11M
Market Cap	934.25M
EPS	$0 ( 2024-04-11 )
Next earnings date	( $-0.800 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.92
ATR14	$0.0230 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Silva Paul M	Buy	25 000	Director Stock Option (right to buy)
2024-05-20	Kunkel Lori Anne	Buy	25 000	Director Stock Option (right to buy)
2024-05-20	Gregory Julia P	Buy	25 000	Director Stock Option (right to buy)
2024-05-20	Lacey David L.	Buy	25 000	Director Stock Option (right to buy)
2024-05-20	Reinsdorf Judith A	Buy	25 000	Director Stock Option (right to buy)

INSIDER POWER
90.52
Last 100 transactions
Buy: 2 423 845 \| Sell: 111 850

Volume Correlation

Long: 0.49 (neutral)

Short: -0.01 (neutral)

Signal:(60.304) Neutral

Nurix Therapeutics, Inc. Correlation

10 Most Positive Correlations
AIRR	0.93
FCYIX	0.926
PIO	0.921
PHO	0.919
FRPT	0.919
GRID	0.916
HOOD	0.916
VSEC	0.915
TTD	0.912
DDIV	0.912

10 Most Negative Correlations
SSP	-0.908
SOFO	-0.907
RAPT	-0.905
AIRS	-0.905
MFIN	-0.896
DBX	-0.896
EEIQ	-0.888
FIVN	-0.887
LTRX	-0.881
ROKU	-0.876

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nurix Therapeutics, Inc. Correlation - Currency/Commodity

0.27
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.30
( neutral )

Nurix Therapeutics, Inc. Financials

Annual	2023
Revenue:	$76.99M
Gross Profit:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Revenue:	$76.99M
Gross Profit:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Revenue:	$38.63M
Gross Profit:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Revenue:	$29.75M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.